

### AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A solid dispersion composition comprising cefditoren pivoxil and at least 0.1 mg, preferably at least 5 mg, 0.1 to 200 mg of a sugar-sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.
2. **(Currently amended)** The solid dispersion composition according to claim 1, comprising 0.1 mg to 200 mg, preferably at least 5 to 100 mg, more preferably 5 to 50 mg, of the sugar-sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.
3. **(Previously presented)** The solid dispersion composition according to claim 1, which further comprises a pharmaceutically acceptable water-soluble polymer.
4. **(Currently amended)** The solid dispersion composition according to claim 3, which contains at least 1 mg, preferably 1 to 100 mg, more preferably 1 to 50 mg, of the water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.
5. **(Currently amended)** The solid dispersion composition according to claim 1, which contains 0.1 to 200 mg of the sugar ester fatty acid and 1 to 100 mg of the water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.
6. **(Currently amended)** The solid dispersion composition according to claim 1, which contains 5 to 100 mg of the sugar-sucrose ester fatty acid and 1 to 50 mg of the a pharmaceutically acceptable water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

7. **(Previously presented)** The solid dispersion composition according to claim 3, wherein the pharmaceutically acceptable water-soluble polymer is one or more water-soluble polymers selected from the group consisting of hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

8. **(Currently amended)** The solid dispersion composition according to claim 1, wherein ~~the~~an amorphousness-maintaining period of cefditoren pivoxil is at least 3 days when suspended in water at a cefditoren pivoxil concentration of 10 mg/ml.

9. **(Previously presented)** An antibiotic pharmaceutical preparation comprising the composition of claim 1 together with a pharmaceutically acceptable additive.

10. **(Currently amended)** A liquid composition comprising cefditoren pivoxil and 0.1 to 200 mg ~~at least 0.1 mg, preferably at least 5 mg, of the~~ a sugar-sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil, which is obtainable by dissolving or suspending ~~a~~the solid dispersion composition of claim 1 in a medium.

11. **(Currently amended)** A liquid composition comprising cefditoren pivoxil and 0.1 to 200 mg ~~at least 0.1 mg, preferably at least 5 mg, of the~~ a sugar-sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil, which is obtainable by dissolving or suspending ~~a~~the pharmaceutical preparation of claim 9 in a medium.